EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Plasma Aβ42/Aβ40 and phospho‐tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease

Robert A Rissman iD, Oliver Langford, Rema Raman, Michael C Donohue, Sara Abdel-Latif, Matthew R Meyer, Traci Wente-Roth, Kristopher M Kirmess, Jennifer Ngolab, Charisse N Winston, Gustavo Jimenez-Maggiora, Michael S Rafii und 9 weitere

Alzheimer's & Dementia · 2024-02 · 20 (2) · 1214-1224

DOI: 10.1002/alz.13542 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 06.11.2023. Verfasst von Robert A Rissman und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences, University of California San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 169-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Incorporating blood‐based Alzheimer's disease biomarkers such as tau and amyloid beta (Aβ) into screening algorithms may improve screening efficiency. METHODS Plasma Aβ, phosphorylated tau (p‐tau)181, and p‐tau217 concentration levels from AHEAD 3–45 study participants were measured using mass spectrometry. Tau concentration ratios for each proteoform were calculated to normalize for inter‐individual differences. Receiver operating characteristic (ROC) curve analysis was performed for each biomarker against amyloid positivity, defined by > 20 Centiloids. Mixture of experts analysis assessed the value of including tau concentration ratios into the existing predictive algorithm for amyloid positron emission tomography status. RESULTS The area under the receiver operating curve (AUC) was 0.87 for Aβ42/Aβ40, 0.74 for phosphorylated variant p‐tau181 ratio (p‐tau181/np‐tau181), and 0.92 for phosphorylated variant p‐tau217 ratio (p‐tau217/np‐tau217). The Plasma Predicted Centiloid (PPC), a predictive model including p‐tau217/np‐tau217, Aβ42/Aβ40, age, and apolipoprotein E improved AUC to 0.95. DISCUSSION Including plasma p‐tau217/np‐tau217 along with Aβ42/Aβ40 in predictive algorithms may streamline screening preclinical individuals into anti‐amyloid clinical trials. ClinicalTrials.gov Identifier: NCT04468659 Highlights The addition of plasma phosphorylated variant p‐tau217 ratio (p‐tau217/np‐tau217) significantly improved plasma biomarker algorithms for identifying preclinical amyloid positron emission tomography positivity. Prediction performance at higher NAV Centiloid levels was improved with p‐tau217/np‐tau217. All models generated for this study are incorporated into the Plasma Predicted Centiloid (PPC) app for public use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseHumansAmyloid beta-PeptidesPeptide FragmentsAmyloidtau ProteinsPositron-Emission TomographyBiomarkers

Stichwörter der Autor:innen

blood-based biomarkersmass spectrometryplasmatau

Substanzen

Amyloid beta-PeptidesPeptide FragmentsAmyloidtau ProteinsBiomarkers

Autor:innen und Institutionen

  • Department of Neurosciences, University of California San Diego, La Jolla, California, USA.
  • Alzheimer's Therapeutic Research Institute, Keck School of Medicine of the University of Southern California, San Diego, California, USA.
  • VA San Diego Healthcare System, San Diego, California, USA.
  • C2N Diagnostics, St. Louis, Missouri, USA.
  • Eisai US, Nutley, New Jersey, USA.
  • Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Robert A Rissman

Förderung

  • NIA NIH HHS
  • NINDS NIH HHS

Zitieren

APA

Rissman, R. A., Langford, O., Raman, R., Donohue, M. C., Abdel-Latif, S., Meyer, M. R., Wente-Roth, T., Kirmess, K. M., Ngolab, J., Winston, C. N., Jimenez-Maggiora, G., Rafii, M. S., Sachdev, P., West, T., Yarasheski, K. E., Braunstein, J. B., Irizarry, M., Johnson, K. A., Aisen, P. S., …, & AHEAD 3-45 Study team (2024). Plasma Aβ42/Aβ40 and phospho‐tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease. Alzheimer's & Dementia, 20(2), 1214-1224. https://doi.org/10.1002/alz.13542

Vancouver

Rissman RA, Langford O, Raman R, Donohue MC, Abdel-Latif S, Meyer MR, et al. Plasma Aβ42/Aβ40 and phospho‐tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease. Alzheimer's & Dementia. 2024;20(2):1214-1224. doi:10.1002/alz.13542

BibTeX
@article{Rissman2024,
  author = {Rissman, Robert A and Langford, Oliver and Raman, Rema and Donohue, Michael C and Abdel-Latif, Sara and Meyer, Matthew R and Wente-Roth, Traci and Kirmess, Kristopher M and Ngolab, Jennifer and Winston, Charisse N and Jimenez-Maggiora, Gustavo and Rafii, Michael S and Sachdev, Pallavi and West, Tim and Yarasheski, Kevin E and Braunstein, Joel B and Irizarry, Michael and Johnson, Keith A and Aisen, Paul S and Sperling, Reisa A and AHEAD 3-45 Study team, AHEAD 3-45 Study team},
  title = {Plasma Aβ42/Aβ40 and phospho‐tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease},
  journal = {Alzheimer's & Dementia},
  year = {2024},
  volume = {20},
  number = {2},
  pages = {1214--1224},
  doi = {10.1002/alz.13542}
}
Kostenlos starten →